Astria Therapeutics (ATXS) announced that it has begun opening clinical trial sites in the European Union and may begin screening participants for the Phase 3 ALPHA-ORBIT trial of navenibart, an investigational monoclonal antibody inhibitor of plasma kallikrein in development for the treatment of hereditary angioedema with the potential for dosing every three and six months.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATXS:
- Astria Therapeutics price target raised to $26 from $25 at Evercore ISI
- Buy Rating for Astria Therapeutics: Promising Clinical Data and Market Advantages of STAR-0310
- Promising Potential of Astria Therapeutics’ STAR-0310 in Atopic Dermatitis: Analyst Recommends Buy
- Astria Therapeutics price target raised to $20 from $16 at H.C. Wainwright
- Astria delivers on all objectives in STAR-0310 trial, says Cantor Fitzgerald